文献速递膀胱癌与上尿路尿路上皮癌

阿替利珠单抗联合放疗膀胱保留治疗肌层浸润性膀胱癌的II期最终分析

Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial.
PubMed 文献 · Eur Urol · 2026-01-17

这项多中心开放标签II期试验评估了阿替利珠单抗联合放疗对cT1-3N0M0肌层浸润性膀胱癌的膀胱保留治疗效果。41例患者接受治疗,24周临床完全缓解率为84%,3年无进展生存率为70%(95%CI 54-81%),3年总生存率为91%,3年膀胱完整无复发生存率为89%。≥3级不良事件发生率为55%,无治疗相关死亡。

要点

  • 阿替利珠单抗联合放疗在肌层浸润性膀胱癌中显示出较好的膀胱保留效果
  • 3年无进展生存率70%,95%CI下限超过预设45%阈值
  • ≥3级不良事件发生率55%,但无治疗相关死亡

核心结论

  • 阿替利珠单抗联合放疗的膀胱保留治疗对不适合或拒绝根治性膀胱切除术的患者显示出有利的治疗效果和可控的毒性。

研究设计与样本

  • 多中心、开放标签、II期试验,纳入cT1-3N0M0肌层浸润性膀胱癌患者,45例入组中41例接受治疗。
  • 治疗方案为盆腔放疗41.4 Gy加全膀胱16.2 Gy,联合阿替利珠单抗1200 mg每3周一次。
  • 主要终点为3年无进展生存率,关键次要终点包括24周临床完全缓解率、总生存率和膀胱完整无复发生存率。

主要发现

  • 24周临床完全缓解率为84%。
  • 3年无进展生存率为70%(95%CI 54-81%),95%CI下限超过预设阈值45%。
  • 3年总生存率为91%,3年膀胱完整无复发生存率为89%。
  • ≥3级不良事件发生率为55%,未观察到治疗相关死亡。

关键数值与推荐

  • 3年无进展生存率70%(95%CI 54-81%),下限超过预设阈值45%。
  • 24周临床完全缓解率84%。
  • 3年总生存率91%,3年膀胱完整无复发生存率89%。

临床怎么用

  • 对于不适合或拒绝根治性膀胱切除术的肌层浸润性膀胱癌患者,阿替利珠单抗联合放疗可作为膀胱保留治疗选择。
  • 治疗毒性可控,≥3级不良事件发生率55%,无治疗相关死亡。

局限性

  • 单臂设计。
  • 队列样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radical cystectomy (RC) is the standard care for muscle-invasive or very high-risk non-muscle-invasive bladder cancer (BC), but optimal management for bladder preservation remains uncertain. In this multicentre, open-label, phase 2 trial, patients with cT1-3 N0 M0 muscle-invasive BC received radiation therapy (RT; 41.4 Gy to the small pelvis and 16.2 Gy to the whole bladder) and atezolizumab (1200 mg) every 3 wk. The primary endpoint was progression-free survival (PFS) at 3 yr. Key secondary endpoints included the clinical complete response (cCR) rate at 24 wk, overall survival (OS), and the bladder-intact recurrence-free rate (BIRFR). From 2019 to 2021, 41 of the 45 patients enrolled received treatment. The median age was 71 yr and most patients (73%) had T2 tumours. At 24 wk, 84% achieved cCR. The 3-yr PFS rate was 70% (95% confidence interval [CI] 54-81%), with the lower limit of the 95% CI exceeding the prespecified threshold of 45%. The 3-yr OS rate was 91% and the 3-yr BIRFR was 89%. Grade ≥3 adverse events occurred in 55% of patients, but no treatment-related deaths were observed. Limitations include the single-arm design and cohort size. Bladder preservation therapy with atezolizumab and RT showed favourable treatment effects with manageable toxicity for patients unfit for or refusing RC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Nagumo Y, Kimura T, Ishikawa H, et al. Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Final Analysis from a Multicentre, Open-label, Prospective Phase 2 Trial. Eur Urol. 2026. PMID: 41548990. doi:10.1016/j.eururo.2025.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。